Paper Details

  1. Home
  2. Paper Details

Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3.

Author: ChenKe, DongYuhong, HanYufei, LiYingxiu, LiuYajing, LuoYong, QinMingze, WangChu, XuLe, YeTianyu, ZhaoYanfang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Hybridization strategy was used to design a series of 4-piperazinyl-2-aminopyrimidine derivatives with dual inhibitory activity against JAK2 and FLT3 enzymes. Compound 14j showed the most balanced in vitro activity and was selected as a promising JAK2/FLT3 dual inhibitor.
Paper Details　
Original Abstract of the Article :
Hybridization strategy is an effective strategy to obtain multi-target inhibitors in drug design. In this study, we assembled the pharmacophores of momelotinib and tandutinib to get a series of 4-piperazinyl-2-aminopyrimidine derivatives. All compounds were tested for the inhibition of JAK2 and FLT3...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejmech.2019.111590

データ提供：米国国立医学図書館（NLM）

Fighting Cancer: A Hybrid Approach to Inhibiting JAK2 and FLT3

Cancer treatment is a constantly evolving field, with researchers exploring innovative approaches to combatting this deadly disease. This research focuses on developing novel drugs that target multiple pathways involved in cancer development. The study explored the potential of a hybrid approach, combining the strengths of two existing drugs, momelotinib and tandutinib, to create a new drug that effectively inhibits both JAK2 and FLT3 enzymes, which play critical roles in the growth and spread of certain cancers. This innovative approach could lead to more effective treatments for patients.

A Double-Edged Sword: Targeting Multiple Pathways in Cancer

The study revealed promising results for a new drug that effectively inhibits both JAK2 and FLT3 enzymes. This dual-targeting approach is like using a double-edged sword to combat cancer cells, attacking them from multiple angles. The researchers identified a compound that showed potent activity against both enzymes, suggesting a potential new weapon in the fight against cancer.

Beyond the Horizon: Hope for New Cancer Therapies

This research offers hope for new cancer therapies that target multiple pathways simultaneously. This could lead to more effective treatments with fewer side effects. Imagine a future where cancer treatments are tailored to individual patients and their unique genetic profiles, using combination therapies that effectively target multiple pathways.

Dr.Camel's Conclusion

This research is like a refreshing oasis in the vast desert of cancer research. It offers a promising approach to developing more effective and targeted cancer treatments by combining the strengths of existing drugs. This research holds great promise for improving the lives of cancer patients and inspiring hope for a future where cancer is no longer a death sentence.
Date :
  1. Date Completed 2019-11-25
  2. Date Revised 2019-11-25
Further Info :

Pubmed ID

31408808

DOI: Digital Object Identifier

10.1016/j.ejmech.2019.111590

Related Literature

Article Analysis
・Effects of momelotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.